Skip to main content
Premium Trial:

Request an Annual Quote

Biocept Liquid Biopsy Testing to be Offered to America's Choice Provider Network Members

NEW YORK (GenomeWeb) – Biocept today announced that its proprietary liquid biopsy oncology diagnostics will be offered to participants in preferred provider organization America's Choice Provider Network. 

San Diego-based Biocept's circulating tumor cell- and DNA-based technology gives clinicians an alternative for testing patients when a tumor biopsy is not adequate or practical. The firm's blood-based tests are also used by physicians to monitor a patient's treatment in a non-invasive manner. The tests are performed at the firm's CLIA-certified and CAP-accredited laboratory. Currently, Biocept offers tests for breast, lung, and gastric cancer. It said it plans to introduce additional CLIA-validated tests for lung, prostate, colorectal, breast and other solid tumors in the coming months.

"Through this collaboration with ACPN, we have expanded access to liquid biopsy to 19 million Americans, giving them an option to avoid additional surgeries for a tissue biopsy, thus reducing costs while improving outcomes,” Amy McNeal, Biocept senior director of strategic reimbursement, said in a statement.